TGFB1 and neoplasm: Therapeutic cotreatment with TGF‐β blockage and anti‐PD‐L1 antibodies reverses TGF‐β signaling‐induced T‐cell exclusion in the center of tumors, which triggers robust antitumor immunity and tumor regression.